The $34 billion private equity powerhouse H.I.G. Capital announced the acquisition of BioVectra in a bid to further expand the Canadian company’s biopharmaceutical business.
The BioVectra leadership team has expanded its presence by expanding capacity with the support of Mallinckrodt Pharmaceuticals in recent years. BioVectra CEO Oliver Technow outlined the company’s growth trajectory that will be supported by H.I.G.
“We believe the company is well positioned to capitalize on the growing demand for its broad set of technical capabilities and exceptional quality track record,” said Mike Gallagher, managing director . . .
Not a subscriber yet? Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators